probenecid has been researched along with Hyperuricemia in 31 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Excerpt | Relevance | Reference |
|---|---|---|
"Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr | 6.73 | Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007) | |
| "Osteoprotegerin (OPG) is a secreted glycoprotein in the regulation of bone turnover." | 5.42 | Changes of plasma concentration of osteoprotegerin and its association with endothelial dysfunction before and after hypouricemic therapy in patients with hyperuricemia. ( Wang, HH; Xiang, GD, 2015) |
| "This network meta-analysis demonstrated an important absolute benefit of dotinurad 4 mg once daily to achieve target serum uric acid and low risk of adverse events for drug treatment of gout or hyperuricemia patients." | 5.41 | Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis. ( Chen, LR; Guo, Y; He, GH; Jiang, FF; Li, YJ; Qian, K; Wang, P; Yang, M; Yang, ZL; Yin, SJ, 2023) |
| " Better understanding of the transporters URAT1 and ABCG2 in particular would appear to provide opportunities for more selective, better tolerated agents to increase the renal clearance of uric acid and thereby control hyperuricemia." | 4.90 | Uricosuric drugs: the once and future therapy for hyperuricemia? ( Bach, MH; Simkin, PA, 2014) |
| " Allopurinol can be used for the prophylactic management of chronic hyperuricemia in patients with CKD, but the recommended decreased dosage may limit efficacy and serious hypersensitivity reactions may preclude its use." | 4.88 | Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review. ( Curiel, RV; Guzman, NJ, 2012) |
| " Chronic hyperuricemia (uric acid serum levels >6." | 4.86 | Crystal arthropathies: recognizing and treating "the gouch". ( Quillen, DM, 2010) |
| "Although the clinical implication of hyperuricemia in chronic kidney disease has been an issue of active debate, recent data suggested a causative role of uric acid (UA) in the development of renal disease." | 3.88 | Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( Kang, DH, 2018) |
| "An existing generalized mass action system model of human uric acid (UA) metabolism was used to formulate the fuzzy optimization method for detecting two types of enzymopathies: hyperuricemia caused by phosphoribosylpyrophosphate synthetase (PRPPS) overactivity and Lesch-Nyhan syndrome." | 3.79 | Fuzzy optimization for detecting enzyme targets of human uric acid metabolism. ( Hsu, KC; Wang, FS, 2013) |
| " This has led to the hypothesis that uric acid may contribute to renal fibrosis and progressive renal disease." | 3.76 | Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells. ( Junwei, Y; Lei, J; Li, F; Mingxia, X; Ping, W; Ruoyun, T; Weichun, H; Xiaohua, W; Yang, Z, 2010) |
| "The characteristic phenomena of acute gouty arthritis are acute arthritis in a middle-aged male, associated with serum uric acid above 6 mg." | 3.63 | Diagnosis and treatment of gouty arthritis. ( TALBOTT, JH, 1953) |
"Treatment with benzbromarone monotherapy (range: 100-200 mg/day; mean 138 mg/day) resulted in 92% of patients reaching target levels sUr | 2.73 | Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. ( Brouwers, JR; Houtman, PM; Jansen, TL; Reinders, MK; van Roon, EN, 2007) | |
| "Epidemiological characteristics of preeclampsia such as its uniqueness to humans and an increased incidence of preeclampsia in multiple pregnancies, increased body mass index, renal and hypertensive disease all have uric acid as their common denominator." | 2.71 | Hyperuricaemia and preeclampsia: is there a pathogenic link? ( Schackis, RC, 2004) |
| " The use of allopurinol has been researched extensively and newer strategies for safer effective dosing are now recommended." | 2.58 | Gout - An update of aetiology, genetics, co-morbidities and management. ( Robinson, PC, 2018) |
| "Although gout is one of the most common forms of inflammatory arthritis, it has been relatively neglected until recently." | 2.55 | Major unanswered questions in the clinical gout field. ( Stamp, LK, 2017) |
| "Probenecid is an uricosuric agent which undergoes extensive hepatic metabolism and whose elimination after high doses may become dose dependent." | 2.43 | Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions. ( Pea, F, 2005) |
| "Gout has significant impact on the quality of life with over-utilisation of health resources." | 1.56 | Burden and management of gout in a multi-ethnic Asian cohort. ( Cheung, PP; Chua, CKT; Lim, AYN; Santosa, A; Teng, GG, 2020) |
| "Hyperuricemia is a central risk factor for gout and increases the risk for other chronic diseases, including cardiometabolic disease, kidney disease, and hypertension." | 1.56 | High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout. ( Dai, S; Guo, Y; Hong, F; Li, L; Liu, G; Pan, S; Qiao, X; Wang, J; Xie, X; Xu, P; Xue, T; Zhai, Y; Zheng, A, 2020) |
| "Hyperuricemia was defined as having a serum urate level of >7." | 1.51 | Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. ( Chen-Xu, M; Choi, HK; Pillinger, MH; Rai, SK; Yokose, C, 2019) |
| "Hyperuricemia is an independent risk factor for progression of kidney disease." | 1.48 | Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease. ( Cheetham, TC; Levy, G; Rashid, N; Shi, JM, 2018) |
| "Osteoprotegerin (OPG) is a secreted glycoprotein in the regulation of bone turnover." | 1.42 | Changes of plasma concentration of osteoprotegerin and its association with endothelial dysfunction before and after hypouricemic therapy in patients with hyperuricemia. ( Wang, HH; Xiang, GD, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.90) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 17 (54.84) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Li, YJ | 1 |
| Chen, LR | 1 |
| Yang, ZL | 1 |
| Wang, P | 1 |
| Jiang, FF | 1 |
| Guo, Y | 2 |
| Qian, K | 1 |
| Yang, M | 1 |
| Yin, SJ | 1 |
| He, GH | 1 |
| Chua, CKT | 1 |
| Cheung, PP | 1 |
| Santosa, A | 1 |
| Lim, AYN | 1 |
| Teng, GG | 1 |
| Hong, F | 1 |
| Zheng, A | 1 |
| Xu, P | 1 |
| Wang, J | 1 |
| Xue, T | 1 |
| Dai, S | 1 |
| Pan, S | 1 |
| Xie, X | 1 |
| Li, L | 1 |
| Qiao, X | 1 |
| Liu, G | 1 |
| Zhai, Y | 1 |
| Cicero, AFG | 1 |
| Fogacci, F | 1 |
| Kuwabara, M | 1 |
| Borghi, C | 1 |
| McMullan, CJ | 1 |
| Borgi, L | 1 |
| Fisher, N | 1 |
| Curhan, G | 1 |
| Forman, J | 1 |
| Kang, DH | 1 |
| Levy, G | 1 |
| Shi, JM | 1 |
| Cheetham, TC | 1 |
| Rashid, N | 1 |
| Robinson, PC | 1 |
| Chen-Xu, M | 1 |
| Yokose, C | 1 |
| Rai, SK | 1 |
| Pillinger, MH | 1 |
| Choi, HK | 1 |
| Kang, EH | 1 |
| Kim, SC | 1 |
| Hsu, KC | 1 |
| Wang, FS | 1 |
| Bach, MH | 1 |
| Simkin, PA | 1 |
| Wang, HH | 1 |
| Xiang, GD | 1 |
| Richette, P | 1 |
| Perez-Ruiz, F | 1 |
| Doherty, M | 1 |
| Jansen, TL | 2 |
| Nuki, G | 1 |
| Pascual, E | 1 |
| Punzi, L | 1 |
| So, AK | 1 |
| Bardin, T | 1 |
| Stamp, L | 1 |
| Dalbeth, N | 1 |
| Stamp, LK | 1 |
| Yang, Z | 1 |
| Xiaohua, W | 1 |
| Lei, J | 1 |
| Ruoyun, T | 1 |
| Mingxia, X | 1 |
| Weichun, H | 1 |
| Li, F | 1 |
| Ping, W | 1 |
| Junwei, Y | 1 |
| Quillen, DM | 1 |
| Hisatome, I | 1 |
| Taniguchi, A | 1 |
| Curiel, RV | 1 |
| Guzman, NJ | 1 |
| Yamanaka, H | 1 |
| TALBOTT, JH | 1 |
| WEISS, W | 1 |
| KAPLAN, A | 1 |
| EISENBERG, GM | 1 |
| FLIPPIN, HF | 1 |
| SMILO, RP | 1 |
| BEISEL, WR | 1 |
| FORSHAM, PH | 1 |
| SCOTT, JT | 1 |
| DIXON, AS | 1 |
| BYWATERS, EG | 1 |
| Schackis, RC | 1 |
| Pea, F | 1 |
| Moreland, LW | 1 |
| Hosoyamada, M | 1 |
| Shibasaki, T | 1 |
| Ichida, K | 1 |
| Reinders, MK | 1 |
| van Roon, EN | 1 |
| Houtman, PM | 1 |
| Brouwers, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-08-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for probenecid and Hyperuricemia
| Article | Year |
|---|---|
Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
Topics: Gout; Gout Suppressants; Humans; Hyperuricemia; Network Meta-Analysis; Probenecid; Randomized Contro | 2023 |
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Topics: Acetamides; Allopurinol; Benzbromarone; Chronic Disease; Evidence-Based Medicine; Febuxostat; Gout S | 2021 |
Gout - An update of aetiology, genetics, co-morbidities and management.
Topics: Allopurinol; Chronic Disease; Comorbidity; Diet; Febuxostat; Gout; Gout Suppressants; Humans; Hyperu | 2018 |
Cardiovascular Safety of Urate Lowering Therapies.
Topics: Allopurinol; Cardiovascular Diseases; Endothelium; Febuxostat; Gout; Gout Suppressants; Heart Failur | 2019 |
Uricosuric drugs: the once and future therapy for hyperuricemia?
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Dis | 2014 |
Improving cardiovascular and renal outcomes in gout: what should we target?
Topics: Allopurinol; Cardiovascular Diseases; Colchicine; Diabetes Mellitus, Type 2; Disease Management; Gou | 2014 |
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
Topics: Allopurinol; Asymptomatic Diseases; Drug Eruptions; Drug Hypersensitivity; Febuxostat; Gout Suppress | 2017 |
Major unanswered questions in the clinical gout field.
Topics: Allopurinol; Benzbromarone; Colchicine; Disease Progression; Febuxostat; Gout; Gout Suppressants; Hu | 2017 |
Crystal arthropathies: recognizing and treating "the gouch".
Topics: Allopurinol; Antimetabolites; Chronic Disease; Colchicine; Febuxostat; Gout; Gout Suppressants; Huma | 2010 |
[Impact of serum uric acid level on the cardiovascular system as a risk factor].
Topics: Adipokines; Benzbromarone; Cardiovascular Diseases; Hyperuricemia; Kidney; Organic Anion Transporter | 2010 |
[Treatment of hyperuricemia and gout based on the guideline for the management of hyperuricemia and gout].
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Benzbromarone; Colchicine; Glucocorticoids; Go | 2010 |
Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Colchicine; Comorbidity; Con | 2012 |
[Drug therapy for idiopathic hyperuricemia--introduction, dose, and side effects].
Topics: Allopurinol; Arteriosclerosis; Benzbromarone; Enzyme Inhibitors; Gout; Humans; Hyperuricemia; Kidney | 2003 |
Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions.
Topics: Allopurinol; Drug Interactions; Humans; Hyperuricemia; Probenecid; Urate Oxidase | 2005 |
[Molecular mechanism in biological transport in the kidney: Urate transporter URAT1].
Topics: Animals; Benzbromarone; Carrier Proteins; Humans; Hyperuricemia; Kidney Tubules; Organic Anion Trans | 2006 |
3 trials available for probenecid and Hyperuricemia
| Article | Year |
|---|---|
Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.
Topics: Adult; Allopurinol; Angiotensin II; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulator | 2017 |
Hyperuricaemia and preeclampsia: is there a pathogenic link?
Topics: Adult; Blood Pressure; Creatine; Female; Humans; Hyperuricemia; Platelet Count; Pre-Eclampsia; Pregn | 2004 |
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Topics: Allopurinol; Benzbromarone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gou | 2007 |
13 other studies available for probenecid and Hyperuricemia
| Article | Year |
|---|---|
Burden and management of gout in a multi-ethnic Asian cohort.
Topics: Adult; Aged; Allopurinol; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Em | 2020 |
High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout.
Topics: Allopurinol; Animal Structures; Animals; Chickens; Crystallization; Diet, High-Protein; Disease Mode | 2020 |
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells.
Topics: Actins; Animals; Antioxidants; Capillaries; Disease Progression; Endothelial Cells; Epithelial-Mesen | 2018 |
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease.
Topics: Aged; Allopurinol; Cohort Studies; Febuxostat; Female; Glomerular Filtration Rate; Gout Suppressants | 2018 |
Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Febuxostat; Female; Gout; Gout Suppressants; Humans; Hy | 2019 |
Fuzzy optimization for detecting enzyme targets of human uric acid metabolism.
Topics: Algorithms; Diet; Drug Design; Drug Discovery; Fuzzy Logic; Humans; Hyperuricemia; Kinetics; Lesch-N | 2013 |
Changes of plasma concentration of osteoprotegerin and its association with endothelial dysfunction before and after hypouricemic therapy in patients with hyperuricemia.
Topics: Adult; Aged; Allopurinol; Endothelium, Vascular; Female; Humans; Hyperuricemia; Male; Middle Aged; O | 2015 |
Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells.
Topics: Animals; Blotting, Western; Cell Line; Disease Models, Animal; Epithelial Cells; Extracellular Matri | 2010 |
Diagnosis and treatment of gouty arthritis.
Topics: Arthritis; Arthritis, Gouty; Colchicine; Gout; Humans; Hyperuricemia; Male; Middle Aged; Probenecid; | 1953 |
The effect of probenecid on pyrazinamide blood levels and pyrazinamide-induced hyperuricemia.
Topics: Humans; Hyperuricemia; Niacin; Nicotinic Acids; Probenecid; Pyrazinamide; Uric Acid | 1957 |
Reversal of thiazide-induced transient hyperuricemia by uricosuric agents.
Topics: Chlorthalidone; Humans; Hydrochlorothiazide; Hyperuricemia; Probenecid; Pyrazoles; Thiazides; Uric A | 1962 |
ASSOCIATION OF HYPERURICAEMIA AND GOUT WITH HYPERPARATHYROIDISM.
Topics: Adenoma; Blood Chemical Analysis; Diagnosis; Gout; Humans; Hyperparathyroidism; Hyperuricemia; Nephr | 1964 |
Febuxostat--treatment for hyperuricemia and gout?
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Probenecid; Thiazoles; Uric | 2005 |